WO2011098483A1 - Pharmaceutical compositions comprising a combination of metformin and sitagliptin - Google Patents
Pharmaceutical compositions comprising a combination of metformin and sitagliptin Download PDFInfo
- Publication number
- WO2011098483A1 WO2011098483A1 PCT/EP2011/051888 EP2011051888W WO2011098483A1 WO 2011098483 A1 WO2011098483 A1 WO 2011098483A1 EP 2011051888 W EP2011051888 W EP 2011051888W WO 2011098483 A1 WO2011098483 A1 WO 2011098483A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metformin
- sitagliptin
- pharmaceutically acceptable
- acceptable salt
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 80
- 229940035748 metformin and sitagliptin Drugs 0.000 title description 21
- 239000000203 mixture Substances 0.000 claims abstract description 251
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 167
- 229960004034 sitagliptin Drugs 0.000 claims abstract description 149
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims abstract description 149
- 229960003105 metformin Drugs 0.000 claims abstract description 141
- 150000003839 salts Chemical class 0.000 claims abstract description 116
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 100
- 239000011159 matrix material Substances 0.000 claims abstract description 100
- 239000002552 dosage form Substances 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 53
- 230000008569 process Effects 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 238000013265 extended release Methods 0.000 claims description 100
- 238000000576 coating method Methods 0.000 claims description 38
- 239000011230 binding agent Substances 0.000 claims description 33
- -1 white wax Substances 0.000 claims description 30
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 239000011248 coating agent Substances 0.000 claims description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 23
- 238000005469 granulation Methods 0.000 claims description 21
- 230000003179 granulation Effects 0.000 claims description 21
- 239000007884 disintegrant Substances 0.000 claims description 20
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000000945 filler Substances 0.000 claims description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 238000007906 compression Methods 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 230000006835 compression Effects 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 6
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004150 EU approved colour Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229940116224 behenate Drugs 0.000 claims description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 3
- 229920000926 Galactomannan Polymers 0.000 claims description 3
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 235000004443 Ricinus communis Nutrition 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 229940092738 beeswax Drugs 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 229940082483 carnauba wax Drugs 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 229920000591 gum Polymers 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229940012831 stearyl alcohol Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001169 thermoplastic Polymers 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 229940045860 white wax Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 description 109
- 239000010410 layer Substances 0.000 description 91
- 238000009472 formulation Methods 0.000 description 77
- 239000008186 active pharmaceutical agent Substances 0.000 description 65
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 45
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 40
- 229960004329 metformin hydrochloride Drugs 0.000 description 21
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 21
- 235000019359 magnesium stearate Nutrition 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 19
- 239000008108 microcrystalline cellulose Substances 0.000 description 19
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 17
- 239000008187 granular material Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- 239000008363 phosphate buffer Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 12
- 239000008119 colloidal silica Substances 0.000 description 12
- 229940069328 povidone Drugs 0.000 description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 9
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 9
- 229920000881 Modified starch Polymers 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 229960004667 ethyl cellulose Drugs 0.000 description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229960001021 lactose monohydrate Drugs 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000005429 MCC/DCP excipient Substances 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229920001531 copovidone Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 229940116317 potato starch Drugs 0.000 description 3
- 229940100486 rice starch Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920003096 Methocel™ K100M Polymers 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007917 core tablet composition Substances 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- NPUOZEMYDHAAMG-UHFFFAOYSA-N hexamagnesium;trisilicate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] NPUOZEMYDHAAMG-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention belongs to the field of pharmaceutical industry and relates to pharmaceutical compositions containing metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and a process for preparing such dosage forms, as well to dosage forms obtained by said process.
- the present invention relates to the use of said dosage form for the treatment of diabetes.
- Sitagliptin is a potent, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor used for the treatment of type II diabetes (Drugs of Today 2007;43:801 -814).
- DPP-IV dipeptidyl peptidase IV
- DPP-IV inhibitors prolong the action of hormone YY, neuropeptides such as substance P, and macrophage-derived chemokines. Potential adverse effects resulting from the prolongation of these messengers include inflammation (effect on substance P), increased blood pressure (effect on neuropeptide Y), and allergic reactions (effect on chemokines).
- DPP-IV activity is related to depressive and anxiety symptoms and immune activation in patients with hepatitis C (Molecular Psychiatry 2001 ;6:475-480) and to the neurogenic inflammation induced by substance P in chronic rhinosinusitis (The FASEB Journal 2002;16:1 132-1 134).
- inhibition of DPP-IV may be a trigger of prostate cancer metastasis (Clin Exp Metastasis 2008;25:765-776 and Int J Cancer 2004;109:855-866) and inhibitors of DPP-IV have the potential to interfere with chemokine-mediated effects including but not limited to allergy (J Immunol 2008;181 :1 120-1 127).
- metformin HCI A combination therapy of sitagliptin with the well established active ingredient of diabetes management metformin HCI provides even more effective treatment of type II diabetes (Drugs Today 2008;44:303-314). Although metformin is effective at lowering blood glucose levels, its use is associated with gastrointestinal (Gl) adverse effects, particularly diarrhea and nausea (Expert Opin Pharmacother 2006;7:803-809). These adverse effects may limit the tolerated dose of metformin and cause patients to discontinue therapy.
- metformin formulations are immediate-release (IR) products, which release the entire drug within 1-2 h after dosing, resulting in high drug concentrations in the Gl tract and consequently in undesired adverse effects.
- IR immediate-release
- WO 2009/1 1 1200 discloses pharmaceutical formulations comprising an inner core tablet composition comprising metformin hydrochloride.
- the inner core is coated with a sustained- release polymer and further comprises a coating comprising an immediate release composition of sitagliptin.
- a sustained- release polymer When dissolving such tablets, firstly the sitagliptin from the immediate release coating is released. After dissolution of the immediate release coating, the sustained-release of the metformin hydrochloride starts.
- EP 1 537 880 A1 discloses sustained release formulations of DPP-IV inhibitors in general, including sitagliptin. Such sustained release formulations comprise DPP-IV inhibitor and hydrophilic polymer.
- WO 2009/099734 discloses pharmaceutical compositions providing an extended release of metformin and an immediate release of sitagliptin.
- the tablet core is comprised of metformin and an extended release excipient (HPMC).
- HPMC extended release excipient
- the tablet core is then coated with immediate release polymer comprising sitagliptin.
- compositions comprising metformin and sitagliptin exist, there is still a need for improved pharmaceutical compositions comprising metformin and sitagliptin as well as an improved process for preparing such preparations.
- the present invention provides the following aspects, subject-matters and preferred embodiments, which respectively taken alone or in combination, further contribute to solving the object of the present invention:
- a pharmaceutical composition comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a
- compartments contains a composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein at least one of the compartments represents an extended release composition, wherein none of said two compartments represents a coating.
- the pharmaceutical composition does not comprise a core which is coated with one or more coatings that contain an API such as metformin and/or sitagliptin.
- metformin and sitagliptin denotes any pharmaceutical acceptable salts of metformin and sitagliptin.
- metalformin preferably refers to the active pharmaceutical ingredient (API) "metformin hydrochloride (HCI)".
- sitagliptin preferably refers to the active pharmaceutical ingredient (API) "sitagliptin phosphate monohydrate”.
- metformin and sitagliptin are sometimes commonly referred to as "API”.
- the compartments are in direct contact with each other (i .e. side by side compartments are formed) or the compartments are separated by a barrier such as an isolating layer.
- a barrier such as an isolating layer.
- composition is a dosage form, preferably the dosage form is a tablet, preferably a multilayer tablet, further preferred a bilayer tablet or a trilayer tablet.
- compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and another compartment contains an extended release or an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
- one compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, and another compartment comprises an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof or metformin or a pharmaceutically acceptable salt thereof.
- one compartment contains an immediate release composition comprising metformin or a pharmaceutically acceptable salt thereof and, preferably, sitagliptin or a pharmaceutically acceptable salt thereof, and another
- compartment comprises an extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof and/or metformin or a pharmaceutically acceptable salt thereof.
- composition preferably the dosage form, comprises at least three compartments.
- one compartment contains an immediate release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an immediate or extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
- one compartment contains an immediate or extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof and one compartment comprises an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
- the extended release composition comprises at least one matrix agent selected from the group consisting of hydrophilic agents, lipophilic agents and inert matrix agents, wherein the hydrophilic matrix agents are selected from the group of pharmaceutical excipients which generate a gel in contact with water, including cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone; polyvinylacetate polymers and copolymers; acrylic acid polymers and copolymers, polyethylene oxide and mixtures thereof;
- the lipophilic matrix agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g. palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof; and
- the inert matrix agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof.
- thermoplastic polymers which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof.
- An extended release compartment according to the present invention which comprises at least one API, wherein preferably the API is sitagliptin or a pharmaceutically acceptable form thereof or metformin or a pharmaceutically acceptable salt thereof, is achieved by using a suitable dissolution rate controlling matrix forming agent (matrix agent) of hydrophilic, lipophilic or inert character, as described above, or a combination of several different matrix agents providing controlled release of the API.
- matrix agent matrix forming agent
- the extended release tablet layer composition does not contain disintegrants and wherein the immediate release layer contains one or more disintegrants but no matrix forming agent.
- the immediate release composition does not comprise a matrix agent, in particular not a matrix agent as specified in item (7).
- the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants, lubricants, sweeteners, glidants, flavourings and colouring agents, preferably the excipients are selected from the group constisting of binding agents, filler-binders, and lubricants.
- the immediate release composition additionally comprises disintegrants.
- Granulation liquids can be added especially if the composition comprises metformin or a pharmaceutically acceptable salt thereof, as also described elsewhere herein. Granulation liquid is removed during further processing of the respective compositions, however, some residual water is required in order that the granulate is compressible.
- composition preferably the pharmaceutical dosage form, according to any one of the previous items, wherein the dosage form is a tablet composed of at least two compartments, preferably at least two layers.
- the tablet comprises two or three layers.
- composition according to any of the preceding items, wherein an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 10-40 wt.-%, preferably 15-
- an extended release compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 15-60 wt.-%, preferably 25-60 wt.-%.
- one of the at least two separate compartments comprises metformin as the only API.
- the composition which comprises metformin as the only API represents an immediate or extended release composition.
- the APIs are contained in separate compartments, potential interactions between the APIs are avoided and the dissolution profile can be defined for each API independent from the dissolution profile of the other API. It has also been found that it is beneficial that the amount of matrix agent in extended release compartments comprising sitagliptin is higher than the amount of matrix agent in extended release compartments comprising metformin. Thus, if a pharmaceutical composition comprises two extended release compartments containing either sitagliptin or metformin, it is preferred that the amount of matrix agent is higher in the compartment containing sitagliptin. Furthermore, in order to keep the total weight of the pharmaceutical composition low, the amount of matrix agent(s) in extended release compartments comprising metformin should be as low as possible.
- the matrix agent is present in a composition (which represents a compartment), which comprises at least metformin (or a pharmaceutically acceptable salt thereof) or only metformin (or a pharmaceutically acceptable salt thereof) as the API, in an amount in the range of 10-40 wt.-%, further preferred in a range of 15-40 wt.-%, also preferred in a range of 15-35 wt.-%, further preferred in a range of 20-30 wt.-%.
- a composition which represents a compartment
- the matrix agent is present in a composition (which represents a compartment), which comprises at least metformin (or a pharmaceutically acceptable salt thereof) or only metformin (or a pharmaceutically acceptable salt thereof) as the API, in an amount in the range of 10-40 wt.-%, further preferred in a range of 15-40 wt.-%, also preferred in a range of 15-35 wt.-%, further preferred in a range of 20-30 wt.-%.
- composition comprising at least metformin or only metformin which contains the matrix agent in an amount of 20-30 wt.-%, if the pharmaceutical dosage form comprises metformin in an amount of at least 500 mg, further preferred at least 850 mg, most preferred at least 1000 mg.
- the matrix agent is present in a composition (which represents a compartment), which comprises at least sitagliptin or a pharmaceutically acceptable salt thereof as the API or only sitagliptin or a pharmaceutically acceptable salt thereof as the API, in an amount in the range of 15-55 wt.-%, further preferred in the range of 30-55 wt.-%, further preferred in the range of 35-50 wt.-%, also preferred in the range of 35-47 wt.-%, further preferred in the range of 35-45 wt.-%.
- a pharmaceutical composition comprising at least one compartment, wherein the compartment contains an extended release composition comprising both metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and wherein the pharmaceutical composition comprises at least one matrix agent.
- the amount of matrix agent(s) is in the range of 10-40 wt.-%, preferably in the range of 15-40 wt.-%, preferably in the range of 15-30 wt.-%, and more preferably in the range of 17-25 wt.-%, in particular in a pharmaceutical composition comprising one extended release composition.
- the matrix agent in the pharmaceutical composition comprising at least one extended release composition is at least one matrix agent selected from the group consisting of lipohilic and inert matrix agents (see item (7)).
- the matrix agent provides for extended release of both metformin and sitagliptin.
- the compartments according to item (12) do not represent a coating.
- coating reference is made to the explanation herein.
- composition does not comprise a core that is coated with one or more coatings that contain an API such as metformin and/or sitagliptin.
- composition preferably the pharmaceutical dosage form, according to any of the previous items, wherein at least one, preferably at least two compartment(s) comprise(s) a matrix agent according to item (7).
- fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogenphosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers and/or filler- binders are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler and/or filler- binder is selected from the group consisting of microcrystalline cellulose and anhydrous dibasic calcium phosphate;
- disintegrants are selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium, (cellulose carboxymethylether sodium salt, crosslinked), starch, such as sodium starch glycolate or corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose, particularly preferred, the disintegrant is croscarmellose sodium;
- the lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate;
- binding agents in compositions such as metformin comprising compositions are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch, particularly preferred, the binding agents are selected from the group consisting of polyvinyl pyrrolidone and/or;
- glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talcum, particularly preferred the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
- composition according to any of the previous items, wherein the pharmaceutical composition is a dosage form that does not contain a significant amount of water or organic solvents that are added from external source.
- does not contain a significant amount of water means that the total amount of water in the pharmaceutical composition is less than 5 wt.-%, preferably less than 3 wt.-%, further preferred less than 2 wt.-% based on the total weight of the pharmaceutical composition.
- the dosage form is a tablet, further preferred a multilayer tablet such as a bi- or a trilayer tablet.
- a process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:
- the compartments represents an extended release composition, and wherein the compositions of step (a) and (b) are not applied in a coating process.
- the compartments are combined so that they are in direct contact with each other (i.e. side by side compartments are formed) or so that they are separated by a barrier such as an isolating layer.
- the terms “are in direct contact” and “side by side compartments are formed” mean that there is no barrier such as an isolating layer between the respective compartments.
- the term "isolating layer” within the meaning of the present invention denotes a layer that does not contain sitagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof. Furthermore, this term also denotes a layer that is free of any API.
- the dosage form is a tablet, preferably a bilayer or a trilayer tablet, which consists of two or three separate compartments, each of which constitutes a layer.
- step a) comprises a granulation step
- preparation of the composition of step b) comprises a mixing or granulation step depending on the API being present in the composition.
- a granulation step is used if the composition comprises metformin. If the composition contains sitagliptin but no metformin, it is preferred to carry out a mixing step only.
- the granulation step comprises a fluid bed granulation.
- This fluid bed granulation can be carried out with any suitable granulation liquid.
- the granulation liquid is demineralized water. In a further preferred
- step b) no granulation liquid is used if only mixing step is required. If metformin is introduced in this step, a granulation step is preferred.
- process step c) involves the use of compression.
- Process step c) is preferably carried out in absence of any solvent added during process step c)
- the omitting of the use of solvents is potentially beneficial regarding the stability of sitagliptin, as there is no potential modification in polymorphism of the API and less potential chemical degradation of the API.
- excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants, lubricants, glidants, flavourings and colouring agents; preferably the excipients are selected from the group constisting of binding agents, filler-binders, and lubricants; further preferred selected from the group consisting of binding agents, filler-binder, disintegrants, lubricants, and glidants.
- Granulation liquid/s may have been incorporated, if at all and if desired, when the
- composition/s comprise/s metformin or a pharmaceutically acceptable salt thereof.
- fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogenphosphate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler is selected from the group consisting of microcrystalline cellulose and anhydrous dibasic calcium phosphate;
- the disintegrants are selected from the group consisting of carmellose calcium,
- carboxymethylstarch sodium croscarmellose sodium
- crospovidone crosslinked polyvinylpyrrolidone
- low-substituted hydroxypropylcellulose particularly preferred, the disintegrant (present only in immediate release compartment) is
- the lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate;
- binding agents preferably used in metformin compartments, are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose,
- the binding agents are selected from the group consisting of polyvinyl pyrrolidone;
- glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talcum, particularly preferred the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica; and/or the sweeteners are selected from the group consisting of aspartame, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin, and the like.
- a process for preparing dosage forms comprising at least one compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprises providing a composition containing metformin or a pharmaceutically acceptable salt thereof, and sitagliptin or a pharmaceutically acceptable salt thereof, and a matrix agent.
- compartments API (e.g. the type of API, for example sitagliptin and metformin, and the amounts used), as well as with regard to the matrix agents (e.g. the type and/or amount of said agents used, reference is made to the indications throughout the whole specification.
- API e.g. the type of API, for example sitagliptin and metformin, and the amounts used
- matrix agents e.g. the type and/or amount of said agents used
- compositions are not applied in a coating process. This means that neither of the compositions is applied onto the other composition, which e.g. forms a compartment, by using a coating process.
- metformin or metformin hydrochloride Although a sustained-release of metformin or metformin hydrochloride is beneficial, it is sometimes desired to have a pharmaceutical dosage form, wherein both APIs, metformin and sitagliptin, are simultaneously dissolved however independent from each other but not necessarily exhibiting the same dissolution profile, and not one after each other.
- coating processes comprise the formation of compositions comprising the API such as sitagliptin in dissolved or suspended form.
- composition and dosage form has been devised which avoids the formation of API containing coating. Especially, omitting the use of solvents prevents any changes of the crystal form of the APIs which tend to be caused by dissolving the APIs when preparing solutions or suspensions containing the API(s).
- the pharmaceutical dosage forms according to the invention are in particular beneficial when using optionally polymorphs or pharmaceutically acceptable salts of the API(s). The maintenance of the respective polymorphs or salts provides for an improved reproducibility of the technological procedure.
- the present invention refers to multilayer tablets (e.g. two or more compartments that each form a layer), wherein the layers are placed upon each but do not represent tablets having a core having several layers around the core.
- multilayer tablets e.g. two or more compartments that each form a layer
- all layers at the same time are (or will become) in contact with the dissolution medium, whereas the tablets having an API-containing core with an API-containing layer around the core are dissolved layer by layer.
- the tablets according to the invention having at least two compartments provide a dissolution profile for the API(s) in each compartments without being significantly affected by the other compartment(s).
- tablets containing an API-containing core and API- containing coatings around the core do not allow designing the dissolution profile of each coating layer without any influence of the outer coating layers.
- the outer coating layer comprising one or more API(s) will firstly be dissolved and only after this, the inner coating layer(s) will be dissolved.
- extended-release formulations containing metformin and/or sitagliptin have several potential advantages over conventional immediate release (IR) tablets.
- the frequency of dosing can be reduced to once daily instead of two or three times daily, thereby avoiding unwanted side effects.
- the gradual release of metformin and/or sitagliptin into the gastrointestinal (Gl) tract provides lower peak gastrointestinal concentrations, thus reducing the incidence of nausea and diarrhea.
- a more uniform metformin and/or sitagliptin blood plasma levels is achieved by extended release metformin and/or sitagliptin formulations.
- the present invention allows releasing/dissolution profiles of metformin and sitagliptin independent from each other, which, in turn, allows for a well targeted and individually controlled release inter-play of the respective APIs: One sustained release API combined with the other sustained or immediate release API, as desired.
- the present invention particularly provides for a very simple process for preparing pharmaceutical dosage forms wherein the compartments simultaneously start providing APIs in an immediate or extended release manner.
- the compartments simultaneously start providing APIs in an immediate or extended release manner.
- Such a mixed immediate/extended release dosage form is particularly advantageous if a part of one or both APIs has to be immediately dissolved and the extended release compartment should at the same time start to slowly release the API.
- improved pharmaceutical dosage forms comprising a combination of metformin and sitagliptin can be prepared by simple compression of blends containing the API(s) into tablets.
- inventive process is simpler, faster and cheaper.
- the dosage forms according to the invention also provide for improved properties e.g. with respect to the dissolution profile and lower possibility for polymorphic changes. Without wishing to be bound by any theory, it is assumed that the dosage forms according to the invention have a lower time lag since all layers start to release
- an immediate and/or extended release compartment containing sitagliptin with an extended release compartment containing metformin in a very simple way, without significant influence on metformin dissolution, which is not possible if sitagliptin is applied as film coating on the core containing metformin. It is also possible to combine both, immediate and/or extended release layer of sitagliptin with immediate and/or extended release layer of metformin.
- the present invention relates to a pharmaceutical composition, preferably a
- compositions comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein at least one of the compartments represents an extended release composition, and wherein none of said two compartments represents a coating.
- compartment within the meaning of the present invention denotes a part of the dosage form comprising one or both pharmaceutically active ingredients (metformin and sitagliptin) and optional other active ingredients, optionally together with excipients as described elsewhere herein.
- the compartments comprise a homogenous mixture of components.
- the active ingredients are metformin and sitagliptin, or the respective pharmaceutically acceptable salts.
- the terms "metformin” and “sitagliptin” respectively include its
- each compartment at least one type of active ingredient is contained. In one embodiment, at least in one, optionally in two compartments both metformin and sitagliptin are present.
- the compartments can comprise immediate or extended release compositions comprising the API(s). According to the invention, at least one of the compartments comprises an extended release composition.
- the compartments are provided in the form of a layer.
- the pharmaceutical dosage form comprising the compartments will then represent monolayer tablets, bilayer tablets, trilayer tablets or multilayer tablets, preferably bilayer tablets.
- all compartments will be or will come in contact with body fluids at the same time, optionally after an outside coating that does not contain an API around the tablet is dissolved.
- the dosage forms according to the present invention have at least two compartments, which are not in the form of a coating. This means that the two compartments which comprise metformin and/or sitagliptin do not represent layers which cover an object such as a core.
- the final dosage form (which is administered to a person in need of) comprises a coating.
- the final dosage form can comprise an outer coating.
- Such a coating does not contain the API being present in the dosage form.
- Such an outer coating can for instance be a film coating such as taste masking, aesthetic or functional coating or the like.
- composition refers to the mixture of API(s) and optional one or more excipients which is comprised by the compartments. This means that the compartments consist of the compositions, wherein the term “compartment” denotes a spatial part of the pharmaceutical composition or dosage form and the term “composition” denotes the constituents of the compartment.
- each of the at least two separate compartments preferably two, respectively constitute a layer.
- the dosage form is a tablet that consists of two or three separate compartments, each of which constitutes a layer.
- coating refers to a layer which completely covers an object and is applied by film coating.
- a compartment according to the invention can be in the form of a layer, wherein the layer can e.g. have the form of a disc and is applied by compaction.
- immediate release denotes that within 2 hours, preferably within 1 .5 h, more preferably within 1 h and most preferably within 30 minutes (min.), equal to or more than 80%, preferably equal to or more than 85%, even more preferably equal to or more than 90% of the API being present in the compartment is dissolved or released, respectively.
- extended release denotes that equal to or more than 95% of the API being present in the compartment are not dissolved or released, respectively, before 2 hours, more preferably not before 3 hours, more preferably not before 4 hours.
- a suitable test for determining the dissolution is the test using Apparatus 2 according to the US Pharmacopoeia 32-NF 27, described in General chapter 71 1 (Dissolution). Conditions chosen for the test were Apparatus 2 with 100 rpm in phosphate buffer medium pH 6.8.
- sitagliptin is in crystalline form.
- sitagliptin can be used in one polymorphic form in the process for preparing the pharmaceutical compositions according to the invention.
- the obtained pharmaceutical compositions comprise sitagliptin in crystalline form, preferably in the same crystal form as was used as a starting material. The omitting of solvents prevents the crystalline sitagliptin to change its polymorphic form or turn into an amorphous form.
- the preferred unit dosage strength of sitagliptin (free base anhydrate) for inclusion into a fixed dose combination dosage form (combination pharmaceutical formulation comprising both metformin and sitagliptin) of the present invention is, preferably, 25, 50 and 100 mg, equivalent to 32.125, 64.25 and 128.5 of sitagliptin phosphate monohydrate, respectively.
- the total amount of sitagliptin contained in the pharmaceutical composition or the pharmaceutical dosage form according to the invention is preferably between 10 mg and 150 mg, preferably between 20 and 1 10 mg.
- the amount of such salts to be present in the pharmaceutical composition or dosage form is calculated based on the amount of sitagliptin as defined above by considering the molecular weight of the pharmaceutically acceptable salt of sitagliptin and the molecular weight of sitagliptin.
- the preferred unit dosage strength of metformin hydrochloride for inclusion into fixed dose combination dosage form (combination pharmaceutical formulation) of the present invention is preferably 500, 750, 850 and 1000 mg, representing the dosage strengths approved in the US for marketing to treat type II diabetes.
- the total amount of metformin hydrochloride contained in the pharmaceutical composition or the pharmaceutical dosage form according to the present invention is preferably between 400 mg and 1500 mg, preferably between 450 and 1 100 mg.
- the amount of such salts to be present in the pharmaceutical composition or dosage form is calculated based on the amount of metformin hydrochloride as defined above by considering the molecular weight of the pharmaceutically acceptable salt of metformin and the molecular weight of metformin hydrochloride.
- the present invention relates to the following preferred fixed-dose combinations of sitagliptin and metformin hydrochloride:
- sitagliptin 25 mg of sitagliptin and 1000 mg of metformin HCI;
- sitagliptin 50 mg of sitagliptin and 500 mg of metformin HCI;
- sitagliptin 50 mg of sitagliptin and 1000 mg of metformin HCI;
- the pharmaceutical composition according to the invention contains both metformin and sitagliptin.
- the pharmaceutical composition contains metformin and sitagliptin as the only APIs.
- the compartments of the pharmaceutical composition or dosage form according to the invention can comprise metformin and/or sitagliptin and, optionally, further API(s).
- the compartments can either represent immediate release compartments or extended release compartments.
- the compartments comprise a composition containing the API(s) and, optionally, one or more pharmaceutically acceptable excipients as described elsewhere herein.
- the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer of the bilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer of the bilayer tablet represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition/dosage form represents a monolayer tablet wherein the monolayer represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin, or pharmaceutically acceptable salt thereof, and the second layer of the bilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or pharmaceutically acceptable salt thereof, and the second layer of the bilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising metformin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising metformin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
- an extended release compartment comprises a matrix agent (polymer) or a combination of several matrix agents (polymers). Further preferred, the extended release compartment comprises a composition comprising a matrix agent (matrix forming agent) of hydrophilic, lipophilic or inert character or a combination of several different matrix agents for providing a controlled release of the drug.
- a matrix agent matrix forming agent
- the matrix agent is present in a extended release composition (which represents a compartment) comprising at least metformin or only metformin as the API in an amount in the range of 10-40 wt.-%, further preferred 15-40 wt.-%, further preferred in a range of 20- 40 wt.-%, also preferred at least 20-35 wt.-%, also preferred in a range of 20 wt.-% to less than 35 wt.-%, further preferred 20-30 wt.-%.
- a extended release composition (which represents a compartment) comprising at least metformin or only metformin as the API in an amount in the range of 10-40 wt.-%, further preferred 15-40 wt.-%, further preferred in a range of 20- 40 wt.-%, also preferred at least 20-35 wt.-%, also preferred in a range of 20 wt.-% to less than 35 wt.-%, further preferred 20-30 wt.-%.
- composition comprising at least metformin or only metformin which contains the matrix agent in an amount of 20-30 wt.-%, if the pharmaceutical dosage form comprises metformin in an amount of at least 500 mg, further preferred at least 850 mg, most preferred at least 1000 mg.
- metformin in an amount of at least 500 mg, further preferred at least 850 mg, most preferred at least 1000 mg.
- the pharmaceutical dosage form becomes very big and less suitable for oral administration, in particular it is disadvantageous when administered to children.
- the matrix agent is present in an extended release composition (which represents a compartment) comprising at least sitagliptin or only sitagliptin as the API in an amount in the range of 15-60 wt.-%, further preferred in the range of 25-60 wt.-%, further preferred in the range of 30-60 wt.-%, further preferred in a range of 35-50 wt.-%, even further preferred in a range of 40-50 wt.-%. It has been found that when using a combination of metformin and sitagliptin in one pharmaceutical composition, it is advantageous to provide the extended release composition (which represents a compartment) comprising at least sitagliptin or only sitagliptin as the API in an amount in the range of 15-60 wt.-%, further preferred in the range of 25-60 wt.-%, further preferred in the range of 30-60 wt.-%, further preferred in a range of 35-50 wt.-%, even further preferred in a range of 40-50 wt.-%.
- Preferred matrix forming agents are polymers selected from the group consisting of hydrophilic, lipophilic and inert matrix agents, wherein
- the hydrophilic matrix agents are selected from the group consisting of cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone;
- polyvinylacetate polymers and copolymers acrylic acid polymers and copolymers, polyethylene oxide and mixtures thereof;
- the lipophilic matrix agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g. palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof; and
- the inert matrix agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and the like.
- thermoplastic polymers which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and the like.
- Preferred hydrophilic matrix agents are selected from the group consisting of
- hydroxypropylmethylcellulose (Methocel, e.g. Methocel K100M Premium), hydroxypropyl cellulose, and polyethylene oxide (such as poliox WSR 303)
- preferred lipophilic matrix agents are selected from the group consisting of hydrogenated castor oil, and glyceril behenate
- preferred inert matrix agents are selected from the group consisting of ethylcellulose (such as ethylcellulose Ethocel, e.g. Ethocel 10 FT Premium)
- polymethylmethacrylates such as Eudragit ® RS.
- Two or more kinds of these polymers may be mixed at appropriate ratios for use.
- one or more pharmaceutically acceptable excipient s can be added.
- suitable pharmaceutically acceptable excipients that can be added to the compositions which form the compartments include, but are not limited to, binding agents, fillers, filler-binder, disintegrants (for immediate release compartments), lubricants, sweeteners, glidants, flavourings and colouring agents.
- the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants (for immediate release compartments), and lubricants.
- the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants (for immediate release compartments), and lubricants.
- the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants (for immediate release compartments), and lubricants.
- the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants (for immediate release compartment
- composition additionally contains a granulation liquid.
- a granulation liquid may be used if a granulation step is carried out.
- a granulation step is comprised in the step of providing a composition comprising metformin or a pharmaceutically acceptable salt thereof.
- excipients which can be used in compositions which are either immediate release or extended release compositions.
- immediate release compositions preferably no excipients are added which provide for an extended release of the API(s), e.g. no excipients are used which are indicated above as suitable matrix agents (polymers).
- the excipients can also be used in an optional outer coating of the pharmaceutical composition, preferably of the dosage form. No disintegrants are present in extended release layers.
- any suitable filler and/or filler-binder can be used in the composition/s which form/s the compartment/s.
- Preferred fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts (hydrogenphosphate), such as calcium hydrogenphosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler is selected from the group consisting of microcrystalline cellulose and anhydrous dibas
- any suitable disintegrants can be used in the present invention.
- composition/s which form/s the immediate release compartment/s are selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium (cellulose carboxymethylether sodium salt, crosslinked), starch, such as sodium starch glycolate or corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose; particularly preferred, the disintegrants are selected from the group consisting of croscarmellose sodium.
- any suitable lubricants can be used in the composition/s which form the compartment/s.
- Preferred lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate.
- any suitable binding agents for wet granulation can be used in the composition/s which form the metformin containing compartment/s.
- Preferred binding agents are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch, particularly preferred binding agent is polyvinyl pyrrolidone.
- any suitable glidants can be used in the compositions which form the compartments.
- Preferred glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicat, such as talcum, particularly preferred glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
- the pharmaceutical composition according to the invention is preferably a dosage form, preferably a dosage form that is in a solid form, such as tablets, capsules (soft or hard capsules), caplets, lozenges, and sachets.
- a dosage form according to the present invention is preferably in the form of a tablet. Further preferred the dosage form, preferably the tablet, has at least one layer, preferably at least two layers, further preferred at least three layers. In a further preferred embodiment, the dosage form according to the present invention has one layer, preferably two layers or three layers.
- the present invention also relates to a pharmaceutical composition, preferably a
- pharmaceutical dosage form comprising at least one compartment, wherein the compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and wherein the pharmaceutical composition comprises at least one matrix agent.
- the amount of matrix agent(s) is in the range of 15-40 wt.-%.
- the extended release composition contains at least one matrix agent as defined above.
- the pharmaceutical composition or dosage form might additionally comprise one or more excipients as defined above, as well as an outer API-free coating as described herein.
- the present invention also relates to a process for preparing the pharmaceutical
- compositions according to the invention are provided.
- the present invention relates to a process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:
- the extended release compartment comprising metformin contains a matrix agent in an amount in the range of 15-40 wt.-%, and the extended release
- compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 15-60 wt.-%, further preferred 25-60 wt.-%.
- the compartments are combined so that they are in direct contact with each other (i.e. side by side compartments are formed) or so that they are separated by an isolating layer.
- sitagliptin is not dispersed in water during the process (as it would e.g. be the case during the preparation of a coating).
- “are in direct contact” reference is made to the specification above, as well as with regard to further amounts of the respective matrix agent/s.
- the compartments being in direct contact with each other offer the advantage that the process according to the present invention is improved in that the process is faster and cheaper compared to conventional processes comprising the formation of a layer that is between the respective compartments containing the API.
- process step c) is carried out in absence of any solvent; preferably process step c) involves the use of compression.
- compositions which form the compartment/s are prepared.
- the compositions comprise metformin and/or sitagliptin and optional further API(s), matrix agents and one or more excipients.
- the excipients are selected from the group consisting of binding agents, fillers, filler-binder, disintegrants (only for immediate release compartments), lubricants, glidants, flavourings and colouring agents. Preferred excipients and matrix agents are described above.
- the compositions can be prepared by using suitable, well known methods such as mixing, high shear mixing, blending, sieving, granulating, lyophilization or milling of the ingredients.
- the compositions are prepared by using a method which is suitable for use of the compositions in a
- the preparation of the composition provided in step a) comprises a wet granulation step
- the preparation of the composition of step b) comprises a mixing step and/or granulation step.
- the preparation of said composition comprises a granulation step. If a granulation step is comprised, a granulation liquid is used.
- process step c) involves the use of compression. If an extended release compartment is prepared, a matrix agent is added to the composition and no disintegrant is added. If an immediate release compartment is prepared, a disintegant is added and no matrix agent is added to the composition.
- compositions which form the compartments are pressed into the final dosage form like tablets. Further preferred a compression process is applied.
- the compression process is applied.
- a tablet press capable of compressing multilayered, particular bilayered, tablets is used.
- a tablet press can be any tablet press that fulfils the above criteria, preferably a Riva bilayered tablet press is used.
- the first and second compositions may be compressed in a bilayered tablet press in a well known bilayer tabletting mode.
- the process is carried out in order that each of the compartments constitutes a layer.
- the dosage form is a tablet, preferably a bilayer or trilayer tablet, which consists of two or three separate compartments, each of which constitutes a layer.
- the present invention also relates to a dosage form, obtained according to a process according to the present invention.
- the present invention refers to the use of a dosage form according to any of the preceding items, for the treatment of diabetes.
- an API-free outer coating can be applied.
- Such outer coatings can e.g. be functional coatings such as film coatings. Further possible outer coatings are for instance coatings that improve the palatability or
- Such optional outer coating/s can comprise one or more of the excipients as described above.
- process step a) a composition comprising both APIs and a matrix agent is provided and step b) is optional.
- step c) involves a compression step.
- Figure 1 shows the percentage of sitagliptin dissolved from formulations described in
- Figure 2 shows the percentage of metformin dissolved from formulations described in
- Figure 3 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 10, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 4 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 1 1 , tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 5 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 12, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 6 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 13, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 7 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 14, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 8 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 15, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 9 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 16, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 10 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 17, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 11 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 18, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 12 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 19, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Figure 13 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 20, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
- Sitagliptin phosphate monohydrate is mixed with anhydrous dibasic calcium phosphate, microcrystalline cellulose and croscarmellose sodium and sieved through an appropriate sieve.
- Sieved magnesium stearate is added and the composition blended for short period of time.
- the blend is compressed into a bilayer tablet as disclosed in Examples 10, 1 1 , 13, 14 and 16.
- Comparative Example 2 Sitagliptin extended release formulation comprising a hydrophilic matrix agent- Formulation 002S
- Sitagliptin phosphate monohydrate, HPMC and microcrystalline cellulose are homogenously blended and sieved through appropriate sieve.
- Sieved magnesium stearate is added and blended for a short period of time. The blend is compressed into a bilayer tablet as disclosed in Example 12.
- the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
- Comparative Example 3 Sitagliptin extended release formulation comprising a lipophilic matrix agent - Formulation 003S.
- Sitagliptin phosphate monohydrate, hydrogenated castor oil and microcrystalline cellulose are homogenously blended and sieved through an appropriate sieve.
- Sieved magnesium stearate is added and blended for short period of time.
- the blend is compressed into a bilayer tablet as disclosed in Example 15.
- the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
- Example 4 Sitagliptin extended release formulation comprising an inert matrix agent- 004S.
- Sitagliptin phosphate monohydrate, ethylcellulose and microcrystalline cellulose are homogenously blended and sieved through an appropriate sieve.
- Sieved magnesium stearate is added and blended for short period of time.
- the blend is compressed into a bilayer tablet as disclosed in Example 17.
- the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
- Example 5 Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 001 M
- Metformin hydrochloride is screened through 1 mm sieve. Screened metformin hydrochloride and hydroxypropylmethylcellulose are granulated in fluid bed granulator with demineralized water and dried in the same device. Dried granulate is screened through 1 mm sieve.
- Obtained granulate and microcrystalline cellulose are homogenously blended in a bin blender.
- Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into a bilayer tablet as disclosed in Example 10.
- Example 6 Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 002M
- Metformin hydrochloride is screened through 1 mm sieve. Screened metformin hydrochloride is granulated in a fluid bed granulator with a solution of povidone in demineralized water and dried in the same device. The dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydroxypropylmethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into a bilayer tablet as disclosed in Examples 1 1 in 12.
- Example 7 Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 003M
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
- hydrochloride is granulated in a fluid bed granulator with a solution of povidone in
- demineralized water and dried in the same device.
- the dried granulate is screened through a 1 mm sieve.
- the obtained granulate, microcrystalline cellulose and hydroxypropylcellulose are homogenously blended in a bin blender.
- Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into a bilayer tablet as disclosed in Examples 13.
- Example 8 Metformin extended release formulation comprising a lipophilic matrix agent - Formulation 004M
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
- hydrochloride is granulated in fluid bed granulator with the solution of povidone in
- demineralized water and dried in the same device.
- the dried granulate is screened through a 1 mm sieve.
- the obtained granulate, microcrystalline cellulose and hydrogenated castor oil are homogenously blended in a bin blender.
- Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into a bilayer tablet as disclosed in Examples 14 and 15.
- Example 9 Metformin extended release formulation comprising an inert matrix agent - Formulation 005M
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
- hydrochloride is granulated in a fluid bed granulator with a solution of povidone in demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and ethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in bin blender so that the final blend is obtained.
- the final blend is compressed into a bilayer tablet as disclosed in Examples 16 and 17.
- Example 10 Bilayer tablets Formulation 001 N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 001 M disclosed in example 5 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
- the first and the second layer according to the composition in the table above are compressed into bilayer tablets.
- Example 1 1 Bilayer tablets - Formulation 002N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 002M disclosed in example 6 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
- Example 12 Bilayer tablets - Formulation 002N/2-XR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 002M disclosed in example 6 and as a second layer an extended release formulation of sitagliptin comprising hydrophilic matrix - Formulation 002S disclosed in example 2.
- the first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
- Example 13 Bilayer tablets - Formulation 003N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 003M disclosed in example 7 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
- the first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
- Example 14 Bilayer tablets - Formulation 004N/2-IR containing as a first layer an extended release formulation of metformin comprising a lipophilic matrix agent - Formulation 004M disclosed in example 8 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
- metformin comprising 1500.000 lipophilic matrix agent
- the first and the second layer according to the composition in the table above are compressed into bilayer tablets.
- Example 15 Bilayer tablets - Formulation 004N/2-XR containing as a first layer an extended release formulation of metformin comprising a lipophilic matrix agent - Formulation 004M disclosed in example 8 and as a second layer an extended release formulation of sitagliptin comprising a lipophilic matrix - Formulation 003S disclosed in example 3.
- the first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
- Example 16 Bilayer tablets - Formulation 005N/2-IR containing as a first layer an extended release formulation of metformin comprising an inert matrix agent - Formulation 005M disclosed in example 9 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
- Example 17 Bilayer tablets - Formulation 005N/2-XR containing as a first layer an extended release formulation of metformin comprising an inert matrix agent - Formulation 005M disclosed in example 9 and as a second layer extended release formulation of sitagliptin comprising an inert matrix - Formulation 004S disclosed in example 4.
- the first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
- Example 18 Extended release formulation of a combination of metformin and sitagliptin comprising a hydrophilic matrix agent - Formulation 007N.
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
- hydrochloride and sitagliptin phosphate monohydrate are granulated in a fluid bed granulator with a solution of povidone in demineralized water and dried in the same device.
- the dried granulate is screened through a 1 mm sieve.
- the obtained granulate, microcrystalline cellulose and hydroxypropylmethylcellulose are homogenously blended in a bin blender.
- Pre- sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that final blend is obtained.
- the final blend is compressed into monolayer tablets.
- Example 19 Extended release formulation of combination of metformin and sitagliptin comprising a lipophilic matrix agent - Formulation 008N
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
- hydrochloride and sitagliptin phosphate monohydrate are granulated in a fluid bed granulator with the solution of povidone in demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydrogenated castor oil are homogenously blended in a bin blender. Pre- sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into monolayer tablets.
- Example 20 Extended release formulation of combination of metformin and sitagliptin comprising an inert matrix agent - Formulation 009N.
- Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin hydrochloride and sitagliptin phosphate monohydrate are granulated in fluid bed granulator with the solution of povidone in demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and ethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
- the final blend is compressed into monolayer tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a pharmaceutical composition, preferably a pharmaceutical dosage form, comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin. The present invention also relates to a process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of: a) providing one composition containing metformin or a pharmaceutically acceptable salt thereof and optionally also sitagliptin, b) providing a further composition containing sitagliptin or a pharmaceutically acceptable salt thereof and optionally also metformin, and c) combining the compositions to form compartments. The present invention also refers to a process for preparing dosage forms comprising at least one compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprises providing a composition containing metformin or a pharmaceutically acceptable salt thereof, and sitagliptin or a pharmaceutically acceptable salt thereof, and a matrix agent. Moreover, the present invention related to a dosage form obtained by said process, and to the use of said dosage form for the treatment of diabetes.
Description
Pharmaceutical compositions comprising a combination of metformin and sitagliptin Field of the invention
The present invention belongs to the field of pharmaceutical industry and relates to pharmaceutical compositions containing metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and a process for preparing such dosage forms, as well to dosage forms obtained by said process.
Furthermore, the present invention relates to the use of said dosage form for the treatment of diabetes.
Description of the background art
Sitagliptin is a potent, orally active dipeptidyl peptidase IV (DPP-IV) inhibitor used for the treatment of type II diabetes (Drugs of Today 2007;43:801 -814). There is a number of substrates beyond metabolic control that DPP-IV cleaves, and therefore inhibit their action, including hormones, neuropeptides, and chemokines. DPP-IV inhibitors prolong the action of hormone YY, neuropeptides such as substance P, and macrophage-derived chemokines. Potential adverse effects resulting from the prolongation of these messengers include inflammation (effect on substance P), increased blood pressure (effect on neuropeptide Y), and allergic reactions (effect on chemokines). Particularly, lower serum DPP-IV activity is related to depressive and anxiety symptoms and immune activation in patients with hepatitis C (Molecular Psychiatry 2001 ;6:475-480) and to the neurogenic inflammation induced by substance P in chronic rhinosinusitis (The FASEB Journal 2002;16:1 132-1 134). Furthermore, inhibition of DPP-IV may be a trigger of prostate cancer metastasis (Clin Exp Metastasis 2008;25:765-776 and Int J Cancer 2004;109:855-866) and inhibitors of DPP-IV have the potential to interfere with chemokine-mediated effects including but not limited to allergy (J Immunol 2008;181 :1 120-1 127).
A combination therapy of sitagliptin with the well established active ingredient of diabetes management metformin HCI provides even more effective treatment of type II diabetes (Drugs Today 2008;44:303-314). Although metformin is effective at lowering blood glucose levels, its use is associated with gastrointestinal (Gl) adverse effects, particularly diarrhea and nausea (Expert Opin Pharmacother 2006;7:803-809). These adverse effects may limit the tolerated dose of metformin and cause patients to discontinue therapy.
Most currently available metformin formulations are immediate-release (IR) products, which release the entire drug within 1-2 h after dosing, resulting in high drug concentrations in the Gl tract and consequently in undesired adverse effects.
WO 2009/1 1 1200 discloses pharmaceutical formulations comprising an inner core tablet composition comprising metformin hydrochloride. The inner core is coated with a sustained- release polymer and further comprises a coating comprising an immediate release composition of sitagliptin. When dissolving such tablets, firstly the sitagliptin from the
immediate release coating is released. After dissolution of the immediate release coating, the sustained-release of the metformin hydrochloride starts.
EP 1 537 880 A1 discloses sustained release formulations of DPP-IV inhibitors in general, including sitagliptin. Such sustained release formulations comprise DPP-IV inhibitor and hydrophilic polymer.
WO 2009/099734 discloses pharmaceutical compositions providing an extended release of metformin and an immediate release of sitagliptin. The tablet core is comprised of metformin and an extended release excipient (HPMC). The tablet core is then coated with immediate release polymer comprising sitagliptin.
Although pharmaceutical compositions comprising metformin and sitagliptin exist, there is still a need for improved pharmaceutical compositions comprising metformin and sitagliptin as well as an improved process for preparing such preparations.
Summary of the invention
The present invention provides the following aspects, subject-matters and preferred embodiments, which respectively taken alone or in combination, further contribute to solving the object of the present invention:
(1 ) A pharmaceutical composition comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a
pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein at least one of the compartments represents an extended release composition, wherein none of said two compartments represents a coating.
As described in further detail below, advantageously the pharmaceutical composition does not comprise a core which is coated with one or more coatings that contain an API such as metformin and/or sitagliptin.
The term "metformin" and "sitagliptin" denotes any pharmaceutical acceptable salts of metformin and sitagliptin. Within the meaning of the present invention, the term "metformin" preferably refers to the active pharmaceutical ingredient (API) "metformin hydrochloride (HCI)". Within the meaning of the present invention, the term "sitagliptin" preferably refers to the active pharmaceutical ingredient (API) "sitagliptin phosphate monohydrate". Within the context of the present specification, both metformin and sitagliptin are sometimes commonly referred to as "API".
Preferably, the compartments are in direct contact with each other (i .e. side by side compartments are formed) or the compartments are separated by a barrier such as an isolating layer.
(2) The pharmaceutical composition according to item (1 ), wherein each of the compartments constitutes a layer.
(3) The pharmaceutical composition according to item (1 ) or (2), wherein the
pharmaceutical composition is a dosage form, preferably the dosage form is a tablet, preferably a multilayer tablet, further preferred a bilayer tablet or a trilayer tablet.
(4) The pharmaceutical composition according to any of items (1 ) to (3), wherein the other compartment also represents an extended release composition.
(5) The pharmaceutical composition according to item (1 ) or (2), wherein one
compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and another compartment contains an extended release or an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
In a further preferred embodiment, one compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, and another compartment comprises an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof or metformin or a pharmaceutically acceptable salt thereof.
In another preferred embodiment, one compartment contains an immediate release composition comprising metformin or a pharmaceutically acceptable salt thereof and, preferably, sitagliptin or a pharmaceutically acceptable salt thereof, and another
compartment comprises an extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof and/or metformin or a pharmaceutically acceptable salt thereof.
(6) The pharmaceutical composition according to any of the previous items, wherein the pharmaceutical composition, preferably the dosage form, comprises at least three compartments.
In a preferred embodiment, one compartment contains an immediate release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an immediate or extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
In a preferred embodiment, one compartment contains an immediate or extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and one compartment comprises an extended release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof and one compartment comprises an immediate release composition comprising sitagliptin or a pharmaceutically acceptable salt thereof.
(7) The pharmaceutical composition according to any of the previous items, wherein the extended release composition comprises at least one matrix agent selected from the group consisting of hydrophilic agents, lipophilic agents and inert matrix agents, wherein the hydrophilic matrix agents are selected from the group of pharmaceutical excipients which generate a gel in contact with water, including cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone; polyvinylacetate polymers and copolymers; acrylic acid polymers and copolymers, polyethylene oxide and mixtures thereof;
the lipophilic matrix agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g. palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof; and
the inert matrix agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof.
An extended release compartment according to the present invention which comprises at least one API, wherein preferably the API is sitagliptin or a pharmaceutically acceptable form thereof or metformin or a pharmaceutically acceptable salt thereof, is achieved by using a suitable dissolution rate controlling matrix forming agent (matrix agent) of hydrophilic, lipophilic or inert character, as described above, or a combination of several different matrix agents providing controlled release of the API.
(8) The pharmaceutical composition according to any of the previous items, wherein the immediate release composition does not comprise a matrix agent, in particular not a matrix agent as specified in item (7).
(9) The pharmaceutical composition according to any of the previous items, wherein the extended release tablet layer composition does not contain disintegrants and wherein the immediate release layer contains one or more disintegrants but no matrix forming agent. Preferably, the immediate release composition does not comprise a matrix agent, in particular not a matrix agent as specified in item (7).
The pharmaceutical composition according to the previous item, wherein the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants, lubricants, sweeteners, glidants, flavourings and colouring agents, preferably the excipients are selected from the group constisting of binding agents, filler-binders, and lubricants. Preferably, the immediate release composition additionally comprises disintegrants.
Granulation liquids can be added especially if the composition comprises metformin or a pharmaceutically acceptable salt thereof, as also described elsewhere herein. Granulation liquid is removed during further processing of the respective compositions, however, some residual water is required in order that the granulate is compressible.
(10) The pharmaceutical composition, preferably the pharmaceutical dosage form, according to any one of the previous items, wherein the dosage form is a tablet composed of at least two compartments, preferably at least two layers. Preferably, the tablet comprises two or three layers.
(1 1 ) The pharmaceutical composition according to any of the preceding items, wherein an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 10-40 wt.-%, preferably 15-
40 wt.-%, and wherein an extended release compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 15-60 wt.-%, preferably 25-60 wt.-%.
In another embodiment of the invention, which can be combined with all embodiments as described herein, one of the at least two separate compartments comprises metformin as the only API. In this embodiment, the composition which comprises metformin as the only API represents an immediate or extended release composition.
If the APIs are contained in separate compartments, potential interactions between the APIs are avoided and the dissolution profile can be defined for each API independent from the dissolution profile of the other API. It has also been found that it is beneficial that the amount of matrix agent in extended release compartments comprising sitagliptin is higher than the amount of matrix agent in extended release compartments comprising metformin. Thus, if a pharmaceutical composition comprises two extended release compartments containing either sitagliptin or metformin, it is preferred that the amount of matrix agent is higher in the compartment containing sitagliptin. Furthermore, in order to keep the total weight of the pharmaceutical composition low, the amount of matrix agent(s) in extended release compartments comprising metformin should be as low as possible.
Preferably, the matrix agent is present in a composition (which represents a compartment), which comprises at least metformin (or a pharmaceutically acceptable salt thereof) or only metformin (or a pharmaceutically acceptable salt thereof) as the API, in an amount in the range of 10-40 wt.-%, further preferred in a range of 15-40 wt.-%, also preferred in a range of 15-35 wt.-%, further preferred in a range of 20-30 wt.-%. It is particularly advantageous to provide a composition comprising at least metformin or only metformin which contains the matrix agent in an amount of 20-30 wt.-%, if the pharmaceutical dosage form comprises metformin in an amount of at least 500 mg, further preferred at least 850 mg, most preferred at least 1000 mg.
Further preferred, the matrix agent is present in a composition (which represents a compartment), which comprises at least sitagliptin or a pharmaceutically acceptable salt thereof as the API or only sitagliptin or a pharmaceutically acceptable salt thereof as the API,
in an amount in the range of 15-55 wt.-%, further preferred in the range of 30-55 wt.-%, further preferred in the range of 35-50 wt.-%, also preferred in the range of 35-47 wt.-%, further preferred in the range of 35-45 wt.-%.
(12) A pharmaceutical composition comprising at least one compartment, wherein the compartment contains an extended release composition comprising both metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and wherein the pharmaceutical composition comprises at least one matrix agent.
In a preferred embodiment, the amount of matrix agent(s) is in the range of 10-40 wt.-%, preferably in the range of 15-40 wt.-%, preferably in the range of 15-30 wt.-%, and more preferably in the range of 17-25 wt.-%, in particular in a pharmaceutical composition comprising one extended release composition.
In a further preferred embodiment, the matrix agent in the pharmaceutical composition comprising at least one extended release composition is at least one matrix agent selected from the group consisting of lipohilic and inert matrix agents (see item (7)). The matrix agent provides for extended release of both metformin and sitagliptin.
In a further preferred embodiment, the compartments according to item (12) do not represent a coating. With regard to the term "coating", reference is made to the explanation herein. Furthermore, as described in further detail elsewhere herein, advantageously the
pharmaceutical composition does not comprise a core that is coated with one or more coatings that contain an API such as metformin and/or sitagliptin.
(13) The pharmaceutical composition, preferably the pharmaceutical dosage form, according to any of the previous items, wherein at least one, preferably at least two compartment(s) comprise(s) a matrix agent according to item (7).
(14) The pharmaceutical composition, preferably the pharmaceutical dosage form, according to any of the previous items, wherein
fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogenphosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers and/or filler- binders are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler and/or filler- binder is selected from the group consisting of microcrystalline cellulose and anhydrous dibasic calcium phosphate;
For immediate release layers/compartments only (there is no need for disintegrants in extended release compartments), disintegrants are selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium, (cellulose carboxymethylether sodium salt, crosslinked), starch, such as sodium starch glycolate or
corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose, particularly preferred, the disintegrant is croscarmellose sodium; the lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate;
binding agents in compositions such as metformin comprising compositions are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch, particularly preferred, the binding agents are selected from the group consisting of polyvinyl pyrrolidone and/or;
glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talcum, particularly preferred the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
(15) The pharmaceutical composition according to any of the previous items, wherein the pharmaceutical composition is a dosage form that does not contain a significant amount of water or organic solvents that are added from external source. The term "does not contain a significant amount of water" means that the total amount of water in the pharmaceutical composition is less than 5 wt.-%, preferably less than 3 wt.-%, further preferred less than 2 wt.-% based on the total weight of the pharmaceutical composition.
In a preferred embodiment, the dosage form is a tablet, further preferred a multilayer tablet such as a bi- or a trilayer tablet.
(16) A process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:
a) providing one composition containing metformin or a pharmaceutically acceptable salt and, optionally, also sitagliptin or a pharmaceutically acceptable salt, and
b) providing a further composition containing sitagliptin or a pharmaceutically acceptable salt and, optionally, also metformin or a pharmaceutically acceptable salt, and
c) combining the compositions to form compartments;
wherein at least one of the compartments represents an extended release composition, and wherein the compositions of step (a) and (b) are not applied in a coating process. Preferably, the compartments are combined so that they are in direct contact with each other (i.e. side by side compartments are formed) or so that they are separated by a barrier such as an isolating layer.
The terms "are in direct contact" and "side by side compartments are formed" mean that there is no barrier such as an isolating layer between the respective compartments. The term "isolating layer" within the meaning of the present invention denotes a layer that does not contain sitagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof. Furthermore, this term also denotes a layer that is free of any API.
(17) The process according to item (16), wherein an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof is formed with a matrix agent in an amount in the range of 10-40 wt.-%, further preferred 15-40 wt.-%, and wherein an extended release compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof is formed with a matrix agent in an amount in the range of 15-60 wt.-%, further preferred 25-60 wt.-%.
Further preferred ranges of the matrix agents in the respective extended release compartment are e.g. described above, see item (1 1 ).
(18) The process according to item (16) or (17), wherein each of the compartments constitutes a layer.
(19) The process according to any of items (16) to (18), wherein the dosage form is a tablet, preferably a bilayer or a trilayer tablet, which consists of two or three separate compartments, each of which constitutes a layer.
(20) The process according to any of items (16) to (19), wherein the preparation of the composition provided in step a) comprises a granulation step, and wherein the preparation of the composition of step b) comprises a mixing or granulation step depending on the API being present in the composition. In general, it is preferred that a granulation step is used if the composition comprises metformin. If the composition contains sitagliptin but no metformin, it is preferred to carry out a mixing step only.
In a further embodiment, the granulation step comprises a fluid bed granulation. This fluid bed granulation can be carried out with any suitable granulation liquid. In a preferred embodiment, the granulation liquid is demineralized water. In a further preferred
embodiment, in step b) no granulation liquid is used if only mixing step is required. If metformin is introduced in this step, a granulation step is preferred.
(21 ) The process according to any of items (16) to (20), wherein process step c) involves the use of compression. Process step c) is preferably carried out in absence of any solvent added during process step c) The omitting of the use of solvents is potentially beneficial regarding the stability of sitagliptin, as there is no potential modification in polymorphism of the API and less potential chemical degradation of the API.
(22) The process according to the previous item, wherein the compositions which form the layers are compressed onto each other sequentially.
(23) The process according to any of items (16) to (22), wherein matrix agent(s) and optional one or more further excipients are incorporated in the respective compositions.
(24) The process according to any of the previous items, wherein the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants, lubricants, glidants, flavourings and colouring agents; preferably the excipients are selected
from the group constisting of binding agents, filler-binders, and lubricants; further preferred selected from the group consisting of binding agents, filler-binder, disintegrants, lubricants, and glidants.
Granulation liquid/s may have been incorporated, if at all and if desired, when the
composition/s comprise/s metformin or a pharmaceutically acceptable salt thereof.
(25) The process according to item (23) or (24), wherein
fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch, cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts, such as calcium hydrogenphosphate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler is selected from the group consisting of microcrystalline cellulose and anhydrous dibasic calcium phosphate;
the disintegrants are selected from the group consisting of carmellose calcium,
carboxymethylstarch sodium, croscarmellose sodium, (cellulose carboxymethylether sodium salt, crosslinked), starch, such as sodium starch glycolate or corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose, particularly preferred, the disintegrant (present only in immediate release compartment) is
croscarmellose sodium;
the lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate;
binding agents, preferably used in metformin compartments, are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose,
hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch, particularly preferred, the binding agents are selected from the group consisting of polyvinyl pyrrolidone;
glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicate, such as talcum, particularly preferred the glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica; and/or the sweeteners are selected from the group consisting of aspartame, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin, and the like.
(26) A dosage form, obtained according to a process according to any of the previous items.
(27) The dosage form according to any of the preceding items for the manufacturing of a medicament for treatment of diabetes.
(28) A process for preparing dosage forms comprising at least one compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprises providing a composition containing metformin or a pharmaceutically acceptable salt thereof, and sitagliptin or a pharmaceutically acceptable salt thereof, and a matrix agent.
With regard to the dosage forms, compartments, API (e.g. the type of API, for example sitagliptin and metformin, and the amounts used), as well as with regard to the matrix agents (e.g. the type and/or amount of said agents used, reference is made to the indications throughout the whole specification.
In a further preferred embodiment, the compositions are not applied in a coating process. This means that neither of the compositions is applied onto the other composition, which e.g. forms a compartment, by using a coating process.
Detailed description of the invention
The present invention is now described in more detail by preferred embodiments and examples, which are however presented for illustrative purpose only and shall not be understood as limiting the scope of the present invention in any way.
Although a sustained-release of metformin or metformin hydrochloride is beneficial, it is sometimes desired to have a pharmaceutical dosage form, wherein both APIs, metformin and sitagliptin, are simultaneously dissolved however independent from each other but not necessarily exhibiting the same dissolution profile, and not one after each other.
It has also been unexpectedly found that changes in polymorphism with respect to the APIs, in particular with respect to the API sitagliptin and pharmaceutically acceptable salts thereof, can be avoided if the use of any solvents like water or organic solvents is omitted. In particular, coating processes comprise the formation of compositions comprising the API such as sitagliptin in dissolved or suspended form. According to the invention, a
pharmaceutical composition and dosage form has been devised which avoids the formation of API containing coating. Especially, omitting the use of solvents prevents any changes of the crystal form of the APIs which tend to be caused by dissolving the APIs when preparing solutions or suspensions containing the API(s). Thus, the pharmaceutical dosage forms according to the invention are in particular beneficial when using optionally polymorphs or pharmaceutically acceptable salts of the API(s). The maintenance of the respective polymorphs or salts provides for an improved reproducibility of the technological procedure.
Furthermore, it has been found that providing different compartments comprising APIs advantageously allows designing the most beneficial release profile for each compartment of the pharmaceutical composition. In particular, the present invention refers to multilayer tablets (e.g. two or more compartments that each form a layer), wherein the layers are placed upon each but do not represent tablets having a core having several layers around
the core. When dissolving such multilayer tablets according to the invention, all layers at the same time are (or will become) in contact with the dissolution medium, whereas the tablets having an API-containing core with an API-containing layer around the core are dissolved layer by layer. As can be derived from the experiments as provided herein (compare figures 1 -13), the tablets according to the invention having at least two compartments provide a dissolution profile for the API(s) in each compartments without being significantly affected by the other compartment(s). By contrast, tablets containing an API-containing core and API- containing coatings around the core do not allow designing the dissolution profile of each coating layer without any influence of the outer coating layers. When dissolving such coated layers, inevitably the outer coating layer comprising one or more API(s) will firstly be dissolved and only after this, the inner coating layer(s) will be dissolved.
As to the dissolution profiles of the respective APIs being present in the respective compartment, extended-release formulations containing metformin and/or sitagliptin have several potential advantages over conventional immediate release (IR) tablets. First, the frequency of dosing can be reduced to once daily instead of two or three times daily, thereby avoiding unwanted side effects. The gradual release of metformin and/or sitagliptin into the gastrointestinal (Gl) tract provides lower peak gastrointestinal concentrations, thus reducing the incidence of nausea and diarrhea. Additionally, a more uniform metformin and/or sitagliptin blood plasma levels is achieved by extended release metformin and/or sitagliptin formulations. These advantages contribute to improved patient adherence with metformin and/or sitagliptin therapy. Yet, the present invention allows releasing/dissolution profiles of metformin and sitagliptin independent from each other, which, in turn, allows for a well targeted and individually controlled release inter-play of the respective APIs: One sustained release API combined with the other sustained or immediate release API, as desired.
The present invention particularly provides for a very simple process for preparing pharmaceutical dosage forms wherein the compartments simultaneously start providing APIs in an immediate or extended release manner. For example, it is possible to provide one compartment with an immediate release of API, whereas the other compartment comprises an extended release composition. Such a mixed immediate/extended release dosage form is particularly advantageous if a part of one or both APIs has to be immediately dissolved and the extended release compartment should at the same time start to slowly release the API.
It has furthermore been found that improved pharmaceutical dosage forms comprising a combination of metformin and sitagliptin can be prepared by simple compression of blends containing the API(s) into tablets. Compared to prior art dosage forms like e.g. tablets comprising an API-containing coating, the inventive process is simpler, faster and cheaper. It is expected that the dosage forms according to the invention also provide for improved properties e.g. with respect to the dissolution profile and lower possibility for polymorphic changes. Without wishing to be bound by any theory, it is assumed that the dosage forms according to the invention have a lower time lag since all layers start to release
simultaneously however independent from each other and not necessarily exhibiting the same dissolution profile. It is also expected that the dosage forms according to the invention possess an improved stability.
An additional benefit of the present invention is the possibility to combine both, an immediate and/or extended release compartment containing sitagliptin with an extended release compartment containing metformin in a very simple way, without significant influence on metformin dissolution, which is not possible if sitagliptin is applied as film coating on the core containing metformin. It is also possible to combine both, immediate and/or extended release layer of sitagliptin with immediate and/or extended release layer of metformin.
Thus, the present invention relates to a pharmaceutical composition, preferably a
pharmaceutical dosage form, comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein at least one of the compartments represents an extended release composition, and wherein none of said two compartments represents a coating.
The term "compartment" within the meaning of the present invention denotes a part of the dosage form comprising one or both pharmaceutically active ingredients (metformin and sitagliptin) and optional other active ingredients, optionally together with excipients as described elsewhere herein. Preferably, the compartments comprise a homogenous mixture of components. According to the present invention, the active ingredients are metformin and sitagliptin, or the respective pharmaceutically acceptable salts. Within the meaning of the present invention, the terms "metformin" and "sitagliptin" respectively include its
pharmaceutically acceptable salts thereof. In each compartment, at least one type of active ingredient is contained. In one embodiment, at least in one, optionally in two compartments both metformin and sitagliptin are present. The compartments can comprise immediate or extended release compositions comprising the API(s). According to the invention, at least one of the compartments comprises an extended release composition.
Preferably, the compartments are provided in the form of a layer. The pharmaceutical dosage form comprising the compartments will then represent monolayer tablets, bilayer tablets, trilayer tablets or multilayer tablets, preferably bilayer tablets. Thus, all compartments will be or will come in contact with body fluids at the same time, optionally after an outside coating that does not contain an API around the tablet is dissolved. Preferably, the dosage forms according to the present invention have at least two compartments, which are not in the form of a coating. This means that the two compartments which comprise metformin and/or sitagliptin do not represent layers which cover an object such as a core. However, it is not excluded that the final dosage form (which is administered to a person in need of) comprises a coating. For example, the final dosage form can comprise an outer coating. Such a coating (outer coating) does not contain the API being present in the dosage form. Such an outer coating can for instance be a film coating such as taste masking, aesthetic or functional coating or the like.
The term "composition" as used herein refers to the mixture of API(s) and optional one or more excipients which is comprised by the compartments. This means that the
compartments consist of the compositions, wherein the term "compartment" denotes a spatial part of the pharmaceutical composition or dosage form and the term "composition" denotes the constituents of the compartment.
Preferably each of the at least two separate compartments, preferably two, respectively constitute a layer. Particularly preferred, according to the present invention, the dosage form is a tablet that consists of two or three separate compartments, each of which constitutes a layer.
The term "coating" as used herein refers to a layer which completely covers an object and is applied by film coating. By contrast, a compartment according to the invention can be in the form of a layer, wherein the layer can e.g. have the form of a disc and is applied by compaction.
Within the meaning of the present invention, the term "immediate release" denotes that within 2 hours, preferably within 1 .5 h, more preferably within 1 h and most preferably within 30 minutes (min.), equal to or more than 80%, preferably equal to or more than 85%, even more preferably equal to or more than 90% of the API being present in the compartment is dissolved or released, respectively.
Furthermore, within the meaning of the present invention, the term "extended release" denotes that equal to or more than 95% of the API being present in the compartment are not dissolved or released, respectively, before 2 hours, more preferably not before 3 hours, more preferably not before 4 hours.
A suitable test for determining the dissolution is the test using Apparatus 2 according to the US Pharmacopoeia 32-NF 27, described in General chapter 71 1 (Dissolution). Conditions chosen for the test were Apparatus 2 with 100 rpm in phosphate buffer medium pH 6.8.
Additionally preferred, sitagliptin is in crystalline form. Advantageously, sitagliptin can be used in one polymorphic form in the process for preparing the pharmaceutical compositions according to the invention. Especially, if the use of solvents is omitted, the obtained pharmaceutical compositions comprise sitagliptin in crystalline form, preferably in the same crystal form as was used as a starting material. The omitting of solvents prevents the crystalline sitagliptin to change its polymorphic form or turn into an amorphous form.
The preferred unit dosage strength of sitagliptin (free base anhydrate) for inclusion into a fixed dose combination dosage form (combination pharmaceutical formulation comprising both metformin and sitagliptin) of the present invention is, preferably, 25, 50 and 100 mg, equivalent to 32.125, 64.25 and 128.5 of sitagliptin phosphate monohydrate, respectively. Thus, the total amount of sitagliptin contained in the pharmaceutical composition or the pharmaceutical dosage form according to the invention is preferably between 10 mg and 150 mg, preferably between 20 and 1 10 mg. If pharmaceutical acceptable salts of sitagliptin are used, the amount of such salts to be present in the pharmaceutical composition or dosage form is calculated based on the amount of sitagliptin as defined above by considering the molecular weight of the pharmaceutically acceptable salt of sitagliptin and the molecular weight of sitagliptin.
The preferred unit dosage strength of metformin hydrochloride for inclusion into fixed dose combination dosage form (combination pharmaceutical formulation) of the present invention is preferably 500, 750, 850 and 1000 mg, representing the dosage strengths approved in the US for marketing to treat type II diabetes. Thus, the total amount of metformin hydrochloride contained in the pharmaceutical composition or the pharmaceutical dosage form according to the present invention is preferably between 400 mg and 1500 mg, preferably between 450 and 1 100 mg. If other pharmaceutical acceptable salts than metformin hydrochloride are used, the amount of such salts to be present in the pharmaceutical composition or dosage form is calculated based on the amount of metformin hydrochloride as defined above by considering the molecular weight of the pharmaceutically acceptable salt of metformin and the molecular weight of metformin hydrochloride.
The present invention relates to the following preferred fixed-dose combinations of sitagliptin and metformin hydrochloride:
25 mg of sitagliptin and 500 mg of metformin HCI;
25 mg of sitagliptin and 750 mg of metformin HCI;
25 mg of sitagliptin and 850 mg of metformin HCI;
25 mg of sitagliptin and 1000 mg of metformin HCI;
50 mg of sitagliptin and 500 mg of metformin HCI;
50 mg of sitagliptin and 750 mg of metformin HCI;
50 mg of sitagliptin and 850 mg of metformin HCI;
50 mg of sitagliptin and 1000 mg of metformin HCI;
100 mg of sitagliptin and 500 mg of metformin HCI;
100 mg of sitagliptin and 750 mg of metformin HCI;
100 mg of sitagliptin and 850 mg of metformin HCI;
100 mg of sitagliptin and 1000 mg of metformin HCI.
The pharmaceutical composition according to the invention contains both metformin and sitagliptin. In a preferred embodiment of the invention, the pharmaceutical composition contains metformin and sitagliptin as the only APIs. As described above, the compartments of the pharmaceutical composition or dosage form according to the invention can comprise metformin and/or sitagliptin and, optionally, further API(s). The compartments can either represent immediate release compartments or extended release compartments. The compartments comprise a composition containing the API(s) and, optionally, one or more pharmaceutically acceptable excipients as described elsewhere herein.
In a preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer of the bilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salts thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an
extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer of the bilayer tablet represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salts thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a monolayer tablet wherein the monolayer represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin, or a pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin, or pharmaceutically acceptable salt thereof, and the second layer of the bilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a bilayer tablet wherein the first layer of the bilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or pharmaceutically acceptable salt thereof, and the second layer of the bilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising metformin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising metformin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof and
the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
In another preferred embodiment of the invention, the pharmaceutical composition/dosage form represents a multilayer tablet, preferably a trilayer tablet, wherein the first layer of the trilayer tablet represents an immediate release compartment comprising metformin or a pharmaceutically acceptable salt thereof and the second layer represents an extended release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof and the third layer of the trilayer tablet represents an immediate release compartment comprising sitagliptin, or pharmaceutically acceptable salt thereof.
It is additionally preferred that an extended release compartment comprises a matrix agent (polymer) or a combination of several matrix agents (polymers). Further preferred, the extended release compartment comprises a composition comprising a matrix agent (matrix forming agent) of hydrophilic, lipophilic or inert character or a combination of several different matrix agents for providing a controlled release of the drug.
Preferably, the matrix agent is present in a extended release composition (which represents a compartment) comprising at least metformin or only metformin as the API in an amount in the range of 10-40 wt.-%, further preferred 15-40 wt.-%, further preferred in a range of 20- 40 wt.-%, also preferred at least 20-35 wt.-%, also preferred in a range of 20 wt.-% to less than 35 wt.-%, further preferred 20-30 wt.-%. It is particularly advantageous to provide a composition comprising at least metformin or only metformin which contains the matrix agent in an amount of 20-30 wt.-%, if the pharmaceutical dosage form comprises metformin in an amount of at least 500 mg, further preferred at least 850 mg, most preferred at least 1000 mg. One reason for this is that the pharmaceutical dosage form becomes very big and less suitable for oral administration, in particular it is disadvantageous when administered to children.
Preferably, the matrix agent is present in an extended release composition (which represents a compartment) comprising at least sitagliptin or only sitagliptin as the API in an amount in the range of 15-60 wt.-%, further preferred in the range of 25-60 wt.-%, further preferred in the range of 30-60 wt.-%, further preferred in a range of 35-50 wt.-%, even further preferred in a range of 40-50 wt.-%. It has been found that when using a combination of metformin and sitagliptin in one pharmaceutical composition, it is advantageous to provide the
aforementioned amounts of matrix agents in order to that the pharmaceutical composition can easily be swallowed.
Preferred matrix forming agents are polymers selected from the group consisting of hydrophilic, lipophilic and inert matrix agents, wherein
the hydrophilic matrix agents are selected from the group consisting of cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone;
polyvinylacetate polymers and copolymers; acrylic acid polymers and copolymers,
polyethylene oxide and mixtures thereof;
the lipophilic matrix agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g. palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof; and
the inert matrix agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and the like.
Preferred hydrophilic matrix agents are selected from the group consisting of
hydroxypropylmethylcellulose (Methocel, e.g. Methocel K100M Premium), hydroxypropyl cellulose, and polyethylene oxide (such as poliox WSR 303), preferred lipophilic matrix agents are selected from the group consisting of hydrogenated castor oil, and glyceril behenate, and preferred inert matrix agents are selected from the group consisting of ethylcellulose (such as ethylcellulose Ethocel, e.g. Ethocel 10 FT Premium), and
polymethylmethacrylates (such as Eudragit® RS).
Two or more kinds of these polymers may be mixed at appropriate ratios for use.
Moreover, one or more pharmaceutically acceptable excipient s can be added. Suitable pharmaceutically acceptable excipients that can be added to the compositions which form the compartments, include, but are not limited to, binding agents, fillers, filler-binder, disintegrants (for immediate release compartments), lubricants, sweeteners, glidants, flavourings and colouring agents. In a preferred embodiment, the excipients are selected from the group consisting of binding agents, fillers, filler-binders, disintegrants (for immediate release compartments), and lubricants. Optionally, in a further embodiment, the
pharmaceutical composition additionally contains a granulation liquid. A granulation liquid may be used if a granulation step is carried out. In an embodiment of the present invention, a granulation step is comprised in the step of providing a composition comprising metformin or a pharmaceutically acceptable salt thereof.
In the following, preferred excipients are described which can be used in compositions which are either immediate release or extended release compositions. However, in case of immediate release compositions, preferably no excipients are added which provide for an extended release of the API(s), e.g. no excipients are used which are indicated above as suitable matrix agents (polymers). The excipients can also be used in an optional outer coating of the pharmaceutical composition, preferably of the dosage form. No disintegrants are present in extended release layers.
According to the present invention, any suitable filler and/or filler-binder can be used in the composition/s which form/s the compartment/s. Preferred fillers and/or filler-binder are selected from the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinized starch, fully pregelatinized starch,
cellulose, such as microcrystalline cellulose or silicified microcrystalline cellulose, mannitol, erythritol, lactose, such as lactose monohydrate and lactose anhydrous, calcium salts (hydrogenphosphate), such as calcium hydrogenphosphate dihydrate, anhydrous dibasic calcium phosphate, sorbitol, and xylitol, particularly preferred, the fillers are selected from the group consisting of pregelatinized starch, microcrystalline cellulose, lactose monohydrate, and lactose, even further preferred the filler is selected from the group consisting of microcrystalline cellulose and anhydrous dibasic calcium phosphate.
According to the present invention, any suitable disintegrants can be used in the
composition/s which form/s the immediate release compartment/s. Preferred disintegrants are selected from the group consisting of carmellose calcium, carboxymethylstarch sodium, croscarmellose sodium (cellulose carboxymethylether sodium salt, crosslinked), starch, such as sodium starch glycolate or corn starch, crosslinked polyvinylpyrrolidone (crospovidone), and low-substituted hydroxypropylcellulose; particularly preferred, the disintegrants are selected from the group consisting of croscarmellose sodium.
According to the present invention, any suitable lubricants can be used in the composition/s which form the compartment/s. Preferred lubricants are selected from the group consisting of stearic acid, talc, sodium stearyl fumarate and magnesium stearate, particularly preferred, the lubricant is magnesium stearate.
According to the present invention, any suitable binding agents for wet granulation can be used in the composition/s which form the metformin containing compartment/s. Preferred binding agents are selected from the group consisting of polyvinyl pyrrolidone (Povidone), copolymers of vinylpyrrolidone with other vinylderivatives (Copovidone), hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, powdered acacia, gelatin, guar gum, carbomer such as carbopol, polymethacrylates and starch, particularly preferred binding agent is polyvinyl pyrrolidone.
According to the present invention, any suitable glidants can be used in the compositions which form the compartments. Preferred glidants are selected from the group consisting of colloidal silica, hydrophobic colloidal silica and magnesium trisilicat, such as talcum, particularly preferred glidants are selected from the group consisting of colloidal silica and hydrophobic colloidal silica.
The pharmaceutical composition according to the invention is preferably a dosage form, preferably a dosage form that is in a solid form, such as tablets, capsules (soft or hard capsules), caplets, lozenges, and sachets. A dosage form according to the present invention is preferably in the form of a tablet. Further preferred the dosage form, preferably the tablet, has at least one layer, preferably at least two layers, further preferred at least three layers. In a further preferred embodiment, the dosage form according to the present invention has one layer, preferably two layers or three layers.
The present invention also relates to a pharmaceutical composition, preferably a
pharmaceutical dosage form, comprising at least one compartment, wherein the
compartment contains an extended release composition comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof and wherein the pharmaceutical composition comprises at least one matrix agent. In a preferred embodiment, the amount of matrix agent(s) is in the range of 15-40 wt.-%.
Preferably, the extended release composition contains at least one matrix agent as defined above. Furthermore, the pharmaceutical composition or dosage form might additionally comprise one or more excipients as defined above, as well as an outer API-free coating as described herein.
The present invention also relates to a process for preparing the pharmaceutical
compositions according to the invention.
Thus, the present invention relates to a process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:
a) providing one composition containing metformin or a pharmaceutically acceptable salt, and, optionally, also sitagliptin or a pharmaceutically acceptable salt, and
b) providing a further composition containing sitagliptin or a pharmaceutically acceptable salt, and, optionally, also metformin or a pharmaceutically acceptable salt, and
c) combining the compositions to form compartments,
wherein at least one of the compartments represents an extended release composition and wherein the compositions of step a) and b) are not applied in a coating process. In a further preferred embodiment, the extended release compartment comprising metformin contains a matrix agent in an amount in the range of 15-40 wt.-%, and the extended release
compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 15-60 wt.-%, further preferred 25-60 wt.-%.
Preferably, the compartments are combined so that they are in direct contact with each other (i.e. side by side compartments are formed) or so that they are separated by an isolating layer.
Further preferred, sitagliptin is not dispersed in water during the process (as it would e.g. be the case during the preparation of a coating).With regard to the term "are in direct contact", reference is made to the specification above, as well as with regard to further amounts of the respective matrix agent/s. The compartments being in direct contact with each other offer the advantage that the process according to the present invention is improved in that the process is faster and cheaper compared to conventional processes comprising the formation of a layer that is between the respective compartments containing the API. Preferably process step c) is carried out in absence of any solvent; preferably process step c) involves the use of compression.
In the process steps a) and b), the compositions which form the compartment/s are prepared. The compositions comprise metformin and/or sitagliptin and optional further API(s), matrix agents and one or more excipients. Preferably, the excipients are selected from the group consisting of binding agents, fillers, filler-binder, disintegrants (only for immediate release compartments), lubricants, glidants, flavourings and colouring agents. Preferred excipients and matrix agents are described above. The compositions can be
prepared by using suitable, well known methods such as mixing, high shear mixing, blending, sieving, granulating, lyophilization or milling of the ingredients. Preferably, the compositions are prepared by using a method which is suitable for use of the compositions in a
subsequent compression step.
In a preferred embodiment, the preparation of the composition provided in step a) comprises a wet granulation step, and the preparation of the composition of step b) comprises a mixing step and/or granulation step. In a further embodiment, if a composition contains sitagliptin and metformin, the preparation of said composition comprises a granulation step. If a granulation step is comprised, a granulation liquid is used.
In a preferred embodiment, process step c) involves the use of compression. If an extended release compartment is prepared, a matrix agent is added to the composition and no disintegrant is added. If an immediate release compartment is prepared, a disintegant is added and no matrix agent is added to the composition.
Preferably the compositions which form the compartments are pressed into the final dosage form like tablets. Further preferred a compression process is applied. Preferably, the
(different) composition/s of the pharmaceutical composition pressed onto each other
Furthermore, compression is the faster and more cost effective compared to coating process (way of tablet preparation). In order to carry out compression, preferably a tablet press capable of compressing multilayered, particular bilayered, tablets is used. Such a tablet press can be any tablet press that fulfils the above criteria, preferably a Riva bilayered tablet press is used. For preparing a tablet according to the present invention, the first and second compositions may be compressed in a bilayered tablet press in a well known bilayer tabletting mode.
Preferably, the process is carried out in order that each of the compartments constitutes a layer. Preferably, the dosage form is a tablet, preferably a bilayer or trilayer tablet, which consists of two or three separate compartments, each of which constitutes a layer.
The present invention also relates to a dosage form, obtained according to a process according to the present invention.
Furthermore, the present invention refers to the use of a dosage form according to any of the preceding items, for the treatment of diabetes.
After the compartments have been formed in process step c), an API-free outer coating can be applied. Such outer coatings can e.g. be functional coatings such as film coatings. Further possible outer coatings are for instance coatings that improve the palatability or
smoothness/gliding ability/sliding ability of the dosage form. Such optional outer coating/s can comprise one or more of the excipients as described above.
It is possible that the process is carried out in the presence of air. This means that it is not necessary to carry out the process in inert atmosphere
The process for preparing a pharmaceutical composition or dosage form having at least one compartment comprising an extended release composition comprising metformin and sitagliptin can be prepared by the process as described above, wherein in step a) a composition comprising both APIs and a matrix agent is provided and step b) is optional. In a further preferred embodiment, process step c) involves a compression step.
The following examples illustrate the process of the present invention and are not intended to limit the scope of the invention set forth in the claims appended hereto.
Description of the Figure:
Figure 1 shows the percentage of sitagliptin dissolved from formulations described in
Examples 1 -4, tested using App.2 at 100 rpm in phosphate buffer medium pH 6.8.
Figure 2 shows the percentage of metformin dissolved from formulations described in
Examples 5-9, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 3 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 10, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 4 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 1 1 , tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 5 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 12, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 6 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 13, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 7 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 14, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 8 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 15, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 9 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 16, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 10 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 17, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 11 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 18, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 12 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 19, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Figure 13 shows the percentage of sitagliptin and metformin dissolved from formulation described in Example 20, tested using App.2; 100 rpm in phosphate buffer medium pH 6.8.
Examples
Comparative Example 1 : Sitagliptin immediate release formulation - Formulation 001 S
*equivalent to 100 mg of free base anhydrate
Sitagliptin phosphate monohydrate is mixed with anhydrous dibasic calcium phosphate, microcrystalline cellulose and croscarmellose sodium and sieved through an appropriate sieve. Sieved magnesium stearate is added and the composition blended for short period of time.
The blend is compressed into a bilayer tablet as disclosed in Examples 10, 1 1 , 13, 14 and 16.
Comparative Example 2: Sitagliptin extended release formulation comprising a hydrophilic matrix agent- Formulation 002S
*equivalent to 100 mg of free base anhydrate
Sitagliptin phosphate monohydrate, HPMC and microcrystalline cellulose are homogenously blended and sieved through appropriate sieve. Sieved magnesium stearate is added and blended for a short period of time.
The blend is compressed into a bilayer tablet as disclosed in Example 12.
Moreover, the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
Comparative Example 3: Sitagliptin extended release formulation comprising a lipophilic matrix agent - Formulation 003S.
*equivalent to 100 mg of free base anhydrate
Sitagliptin phosphate monohydrate, hydrogenated castor oil and microcrystalline cellulose are homogenously blended and sieved through an appropriate sieve. Sieved magnesium stearate is added and blended for short period of time.
The blend is compressed into a bilayer tablet as disclosed in Example 15.
Moreover, the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
Example 4: Sitagliptin extended release formulation comprising an inert matrix agent- 004S.
*equivalent to 100 mg of free base anhydrate
Sitagliptin phosphate monohydrate, ethylcellulose and microcrystalline cellulose are homogenously blended and sieved through an appropriate sieve. Sieved magnesium stearate is added and blended for short period of time.
The blend is compressed into a bilayer tablet as disclosed in Example 17.
Moreover, the tablet blend is compressed into extended release sitagliptin tablets, 300 mg.
Dissolution profiles for Examples 1 -4 are presented in Figure 1.
Example 5: Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 001 M
* removed during the process
Metformin hydrochloride is screened through 1 mm sieve. Screened metformin hydrochloride and hydroxypropylmethylcellulose are granulated in fluid bed granulator with demineralized water and dried in the same device. Dried granulate is screened through 1 mm sieve.
Obtained granulate and microcrystalline cellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into a bilayer tablet as disclosed in Example 10.
Example 6: Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 002M
Methocel K100M Premium agent 350.000 23.33
Magnesium stearate Lubricant
7.500 0.50
Total 1500.000 100.00
* removed during the process
Metformin hydrochloride is screened through 1 mm sieve. Screened metformin hydrochloride is granulated in a fluid bed granulator with a solution of povidone in demineralized water and dried in the same device. The dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydroxypropylmethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into a bilayer tablet as disclosed in Examples 1 1 in 12.
Example 7: Metformin extended release formulation comprising a hydrophilic matrix agent - Formulation 003M
* removed during the process
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
hydrochloride is granulated in a fluid bed granulator with a solution of povidone in
demineralized water and dried in the same device. The dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydroxypropylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into a bilayer tablet as disclosed in Examples 13.
Example 8: Metformin extended release formulation comprising a lipophilic matrix agent - Formulation 004M
* removed during the process
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
hydrochloride is granulated in fluid bed granulator with the solution of povidone in
demineralized water and dried in the same device. The dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydrogenated castor oil are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into a bilayer tablet as disclosed in Examples 14 and 15.
Example 9: Metformin extended release formulation comprising an inert matrix agent - Formulation 005M
* removed during the process
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
hydrochloride is granulated in a fluid bed granulator with a solution of povidone in
demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and ethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in bin blender so that the final blend is obtained.
The final blend is compressed into a bilayer tablet as disclosed in Examples 16 and 17.
Dissolution profiles for Examples 5-9 are presented in Figure 2.
Example 10: Bilayer tablets Formulation 001 N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 001 M disclosed in example 5 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
The first and the second layer according to the composition in the table above are compressed into bilayer tablets.
Example 1 1 : Bilayer tablets - Formulation 002N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 002M disclosed in example 6 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
The first and the second layer according to the composition in the table above are compressed into bilayer tablets.
Example 12: Bilayer tablets - Formulation 002N/2-XR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 002M disclosed in example 6 and as a second layer an extended release formulation of sitagliptin comprising hydrophilic matrix - Formulation 002S disclosed in example 2.
The first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
Example 13: Bilayer tablets - Formulation 003N/2-IR containing as a first layer an extended release formulation of metformin comprising a hydrophilic matrix agent - Formulation 003M disclosed in example 7 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
The first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
Example 14: Bilayer tablets - Formulation 004N/2-IR containing as a first layer an extended release formulation of metformin comprising a lipophilic matrix agent - Formulation 004M disclosed in example 8 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
Ingredient Layer Function amount per tablet
(mg)
final blend 004M first layer extended release formulation
of metformin comprising 1500.000
lipophilic matrix agent
final blend 001 S second layer immediate release
formulation of sitagliptin 300.000
Total bilayer tablet 1800.000
The first and the second layer according to the composition in the table above are compressed into bilayer tablets.
Example 15: Bilayer tablets - Formulation 004N/2-XR containing as a first layer an extended release formulation of metformin comprising a lipophilic matrix agent - Formulation 004M disclosed in example 8 and as a second layer an extended release formulation of sitagliptin comprising a lipophilic matrix - Formulation 003S disclosed in example 3.
The first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
Example 16: Bilayer tablets - Formulation 005N/2-IR containing as a first layer an extended release formulation of metformin comprising an inert matrix agent - Formulation 005M disclosed in example 9 and as a second layer an immediate release formulation of sitagliptin - Formulation 001 S disclosed in example 1 .
The first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
Example 17: Bilayer tablets - Formulation 005N/2-XR containing as a first layer an extended release formulation of metformin comprising an inert matrix agent - Formulation 005M disclosed in example 9 and as a second layer extended release formulation of sitagliptin comprising an inert matrix - Formulation 004S disclosed in example 4.
The first and the second layer according to the compositions in the table above are compressed into bilayer tablets.
Example 18: Extended release formulation of a combination of metformin and sitagliptin comprising a hydrophilic matrix agent - Formulation 007N.
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
hydrochloride and sitagliptin phosphate monohydrate are granulated in a fluid bed granulator with a solution of povidone in demineralized water and dried in the same device. The dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydroxypropylmethylcellulose are homogenously blended in a bin blender. Pre-
sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that final blend is obtained.
The final blend is compressed into monolayer tablets.
Example 19: Extended release formulation of combination of metformin and sitagliptin comprising a lipophilic matrix agent - Formulation 008N
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin
hydrochloride and sitagliptin phosphate monohydrate are granulated in a fluid bed granulator with the solution of povidone in demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and hydrogenated castor oil are homogenously blended in a bin blender. Pre- sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into monolayer tablets.
Example 20: Extended release formulation of combination of metformin and sitagliptin comprising an inert matrix agent - Formulation 009N.
Demineralized water* Granulation liquid - vehicle 677.600
Microcrystalline cellulose Filler / binder 105.250 6.50
Ethylcellulose Ethocel 10 FT Inert matrix agent
Premium 350.000 21 .60
Magnesium stearate Lubricant
8.100 0.50
Total 1620.000 100.00
Metformin hydrochloride is screened through a 1 mm sieve. Screened metformin hydrochloride and sitagliptin phosphate monohydrate are granulated in fluid bed granulator with the solution of povidone in demineralized water and dried in the same device. Dried granulate is screened through a 1 mm sieve. The obtained granulate, microcrystalline cellulose and ethylcellulose are homogenously blended in a bin blender. Pre-sieved magnesium stearate is added to the obtained blend and blended in a bin blender so that the final blend is obtained.
The final blend is compressed into monolayer tablets.
Claims
1 . A pharmaceutical composition comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a
pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein at least one of the compartments represents an extended release composition, and wherein none of said two compartments represents a coating.
2. The pharmaceutical composition according to claim 1 , wherein each of the compartments constitutes a layer.
3. The pharmaceutical composition according to claim 1 or 2, wherein the
pharmaceutical composition is a dosage form, preferably the dosage form is a tablet, preferably a multilayer tablet, further preferred a bilayer tablet or a trilayer tablet.
4. The pharmaceutical composition according to any of claims 1 to 3, wherein the other compartment also represents an extended release composition.
5. The pharmaceutical composition according to any of claims 1 to 4, wherein the extended release composition comprises at least one matrix agent selected from the group consisting of hydrophilic agents, lipophilic agents and inert matrix agents, wherein the hydrophilic matrix agents are selected from the group consisting of cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone;
polyvinylacetate polymers and copolymers; acrylic acid polymers and copolymers and polyethylene oxide and mixtures thereof;
the lipophilic matrix agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g. palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof; and
the inert matrix agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof.
6. The pharmaceutical composition according to any of the preceding claims, wherein the composition contains one or more additional excipients, preferably the excipients are selected from the group consisting of binding agents, fillers, filler-binder, disintegrants, lubricants, glidants, flavourings and colouring agents.
7. The pharmaceutical composition according to any of the preceding claims, wherein an extended release compartment comprising metformin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 10-40 wt.-%, and wherein an extended release compartment comprising sitagliptin or a pharmaceutically acceptable salt thereof contains a matrix agent in an amount in the range of 15-60 wt.-%.
8. A pharmaceutical composition, preferably a pharmaceutical dosage form, comprising at least one compartment, wherein the compartment contains an extended release composition comprising both metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, and wherein the pharmaceutical composition comprises at least one matrix agent.
9. A process for preparing dosage forms comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprising the steps of:
a) providing one composition containing metformin or a pharmaceutically acceptable salt thereof and optionally also sitagliptin,
b) providing a further composition containing sitagliptin or a pharmaceutically acceptable salt thereof and optionally also metformin, and
c) combining the compositions to form compartments,
wherein at least one of the compartments represents an extended release composition, and wherein the compositions of step (a) and (b) are not applied in a coating process.
10. The process according to claim 9, wherein the dosage form represents a tablet and wherein each of the compartments constitutes a layer.
1 1 . The process according to claim 9 or 10, wherein the preparation of the composition provided in step a) comprises a granulation step, and wherein the preparation of the composition of step b) comprises a mixing step.
12. The process according to any of claims 9 to 1 1 , wherein process step c) involves the use of compression.
13. The process according to any of claims 9 to 12, wherein matrix agent(s) and optional one or more further excipients are incorporated in the respective compositions.
14. A dosage form, obtained according to a process according to any of claims 9 to 14.
15. The dosage form according to any of the preceding claims for the manufacturing of a medicament for treatment of diabetes.
16. A process for preparing dosage forms comprising at least one compartment comprising metformin or a pharmaceutically acceptable salt thereof and sitagliptin or a pharmaceutically acceptable salt thereof, the process comprises providing a composition containing metformin or a pharmaceutically acceptable salt thereof, and sitagliptin or a pharmaceutically acceptable salt thereof, and a matrix agent.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11702268A EP2533767A1 (en) | 2010-02-10 | 2011-02-09 | Pharmaceutical compositions comprising a combination of metformin and sitagliptin |
US13/578,596 US8758815B2 (en) | 2010-02-10 | 2011-02-09 | Pharmaceutical compositions comprising a combination of metformin and sitagliptin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10153151.5 | 2010-02-10 | ||
EP10153151A EP2356985A1 (en) | 2010-02-10 | 2010-02-10 | Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011098483A1 true WO2011098483A1 (en) | 2011-08-18 |
Family
ID=42244264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/051888 WO2011098483A1 (en) | 2010-02-10 | 2011-02-09 | Pharmaceutical compositions comprising a combination of metformin and sitagliptin |
Country Status (3)
Country | Link |
---|---|
US (1) | US8758815B2 (en) |
EP (2) | EP2356985A1 (en) |
WO (1) | WO2011098483A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027898A (en) * | 2012-12-28 | 2013-04-10 | 深圳翰宇药业股份有限公司 | Sitagliptin sustained-release pellet and preparation method thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013110085A1 (en) * | 2012-01-20 | 2013-07-25 | Handa Pharmaceuticals, Llc | Oral dosage forms for delivering metformin and sitagliptin |
UY35065A (en) * | 2012-10-08 | 2014-05-30 | Lg Life Sciences Ltd | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION |
EP3033075A1 (en) * | 2013-03-26 | 2016-06-22 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof |
US20150366863A1 (en) * | 2013-03-28 | 2015-12-24 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof |
WO2016016770A1 (en) | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof |
WO2016016772A1 (en) * | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof |
KR102496851B1 (en) * | 2015-04-10 | 2023-02-08 | 제이더블유중외제약 주식회사 | Pharmaceutical composition comprising anagliptin or a pharmaceutically acceptable salt thereof, and metformin or a pharmaceutically acceptable salt thereof and preparation method thereof |
EP4045048A4 (en) | 2019-10-14 | 2023-05-24 | Santa Farma Ilaç Sanayi A.S. | Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics |
IT202100031691A1 (en) * | 2021-12-17 | 2023-06-17 | I B N Savio S R L | PRODUCTION PROCESS OF SUSTAINED RELEASE METFORMIN TABLETS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1537880A1 (en) | 2002-09-11 | 2005-06-08 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
WO2006047248A1 (en) * | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
WO2009099734A1 (en) | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
WO2009111200A1 (en) | 2008-03-04 | 2009-09-11 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
WO2009121945A2 (en) * | 2008-04-03 | 2009-10-08 | Boehringer Ingelheim International Gmbh | New formulations, tablets comprising such formulations, their use and process for their preparation |
-
2010
- 2010-02-10 EP EP10153151A patent/EP2356985A1/en not_active Ceased
-
2011
- 2011-02-09 WO PCT/EP2011/051888 patent/WO2011098483A1/en active Application Filing
- 2011-02-09 EP EP11702268A patent/EP2533767A1/en not_active Withdrawn
- 2011-02-09 US US13/578,596 patent/US8758815B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1537880A1 (en) | 2002-09-11 | 2005-06-08 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
WO2006047248A1 (en) * | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
WO2009099734A1 (en) | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
WO2009111200A1 (en) | 2008-03-04 | 2009-09-11 | Merck & Co., Inc. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
WO2009121945A2 (en) * | 2008-04-03 | 2009-10-08 | Boehringer Ingelheim International Gmbh | New formulations, tablets comprising such formulations, their use and process for their preparation |
Non-Patent Citations (9)
Title |
---|
ABDUL S ET AL: "A flexible technology for modified release of drugs: multi layered tablets", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.JCONREL.2004.03.034, vol. 97, no. 3, 7 July 2004 (2004-07-07), pages 393 - 405, XP004519504, ISSN: 0168-3659 * |
CLIN EXP METASTASIS, vol. 25, 2008, pages 765 - 776 |
DRUGS OF TODAY, vol. 43, 2007, pages 801 - 814 |
DRUGS TODAY, vol. 44, 2008, pages 303 - 314 |
EXPERT OPIN PHARMACOTHER, vol. 7, 2006, pages 803 - 809 |
INT J CANCER, vol. 109, 2004, pages 855 - 866 |
J IMMUNOL, vol. 181, 2008, pages 1120 - 1127 |
MOLECULAR PSYCHIATRY, vol. 6, 2001, pages 475 - 480 |
THE FASEB JOURNAL, vol. 16, 2002, pages 1132 - 1134 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027898A (en) * | 2012-12-28 | 2013-04-10 | 深圳翰宇药业股份有限公司 | Sitagliptin sustained-release pellet and preparation method thereof |
CN103027898B (en) * | 2012-12-28 | 2014-11-26 | 深圳翰宇药业股份有限公司 | Sitagliptin sustained-release pellet and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8758815B2 (en) | 2014-06-24 |
US20130059002A1 (en) | 2013-03-07 |
EP2533767A1 (en) | 2012-12-19 |
EP2356985A1 (en) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11389428B2 (en) | Controlled-release melatonin compositions and related methods | |
US8758815B2 (en) | Pharmaceutical compositions comprising a combination of metformin and sitagliptin | |
JP5816091B2 (en) | Sodium oxybate immediate release dosage form | |
EP1441713B1 (en) | Modified release tamsulosin tablets | |
JP6976946B2 (en) | A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity. | |
EP2986280B1 (en) | Sustained-release formulations of colchicine and methods of using same | |
JP2022190170A (en) | Pharmaceutical combination comprising glucokinase activator and dpp-iv inhibitor, composition, combination preparation, and preparation methods and uses thereof | |
US7915247B1 (en) | Methods of use of fenofibric acid | |
EP2366380A1 (en) | Extended release formulation containing a wax | |
EP2996680A1 (en) | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof | |
CZ298851B6 (en) | Controlled-release tablet for oral administration of active substances | |
WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
JP2023517844A (en) | Pharmaceutical composition containing benzimidazole derivative compound | |
JP2023181218A (en) | Extended release midodrine hydrochloride compositions and methods of use | |
EP3033075A1 (en) | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof | |
KR102409102B1 (en) | pharmaceutical composition | |
US8512746B2 (en) | Extended release pharmaceutical compositions of levetiracetam | |
KR20170001545A (en) | Mosapride sustained-release formulation and Composite formulation comprising mosapride and rabeprazole | |
EP2298290A1 (en) | Controlled release composition comprising levetiracetam | |
US20110195117A1 (en) | Controlled release compositions of ropinirole | |
TW202313072A (en) | Pediatric formulations of ferric citrate | |
CA3226799A1 (en) | Multiparticulate pharmaceutical composition | |
NZ760868B2 (en) | A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11702268 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011702268 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13578596 Country of ref document: US |